This substance is considered compatible with breastfeeding.
Sumatriptan reaches a low concentration in breast milkas well as limited oral bioavailability, making it unlikely their influence on the infant.
Some publications estimate the amount ingested by the baby after the mother subcutaneous injection of 6 mg of active ingredient does not exceed 3.5% of that dose. According to some experts, if the mother refrain from breastfeeding for six hours after administration of the drug, the baby's exposure would be zero.
Warning of the manufacturer:
Sumatriptan has been shown to be excreted in breast milk following subcutaneous administration. Infant exposure can be minimized by avoiding feeding 12 hours after treatment. Breast milk produced in this period should be discarded.